siramesine siramesine siramesine (or lu 28-179) is a sigma receptor agonist, selective for the σ2 subtype. in animal studies, siramesine has been shown to produce anxiolytic and antidepressant effects. it was developed by the pharmaceutical company h lundbeck for the treatment of anxiety, although development was discontinued after clinical trials showed a lack of efficacy in humans. siramesineclinical dataatc codenoneidentifiers iupac name 1'--3h-spiro cas number147817-50-3 ypubchem cid9829526chemspider8005261 nunii3ix8cwr24vcomptox dashboard (epa)dtxsid90163810 chemical and physical dataformulac30h31fn2omolar mass454.589 g·mol−13d model (jsmol)interactive image smiles c1cn(ccc12c3=cc=cc=c3co2)ccccc4=cn(c5=cc=cc=c54)c6=cc=c(c=c6)f inchi inchi=1s/c30h31fn2o/c31-25-12-14-26(15-13-25)33-21-23(27-9-2-4-11-29(27)33)7-5-6-18-32-19-16-30(17-20-32)28-10-3-1-8-24(28)22-34-30/h1-4,8-15,21h,5-7,16-20,22h2 nkey:xwaonogagznusf-uhfffaoysa-n n ny (what is this?) (verify) siramesine has been shown to produce an enhanced antidepressant effect when co-administered with nmda antagonists. it has also been used to study the σ2 activity of cocaine, and has been shown to produce anticancer properties both in vitro and in vivo.